Cargando…

Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database

BACKGROUND: This study aimed to collect data on “triple therapy” for heart failure (HF) with angiotensin-converting enzyme inhibitors (or receptor blockers), β-blockers, and mineralocorticoid receptor antagonists in all eight regions of Japan and clarify the reason for the selection of this therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Daisuke, Inomata, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078795/
https://www.ncbi.nlm.nih.gov/pubmed/33905452
http://dx.doi.org/10.1371/journal.pone.0249711
_version_ 1783685105879875584
author Abe, Daisuke
Inomata, Takayuki
author_facet Abe, Daisuke
Inomata, Takayuki
author_sort Abe, Daisuke
collection PubMed
description BACKGROUND: This study aimed to collect data on “triple therapy” for heart failure (HF) with angiotensin-converting enzyme inhibitors (or receptor blockers), β-blockers, and mineralocorticoid receptor antagonists in all eight regions of Japan and clarify the reason for the selection of this therapeutic approach. METHODS AND RESULTS: We used data from April 2017 to March 2018 from the Medical Data Vision database (380 facilities) to analyze factors impacting triple therapy for HF. Among patients who were hospitalized for HF during the study period, 51,933 patients met the inclusion criteria and underwent further analyses. A reference value of 20.45% from Kanto was used to compare the eight Japanese regions. From the patient cohort, 10,006 (19.27%) patients receiving triple therapy were identified. The highest and lowest rates of triple therapy were in Chugoku (21.90%) and Shikoku (14.27%), respectively, suggesting regional differences in the use of triple therapy at discharge for patients with HF (P < 0.001). Regression analysis revealed a decrease in the administration of triple therapy for patients with chronic kidney disease (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.43–0.48]; P < 0.001), those aged 75 years and older (OR, 0.46, 95% CI: 0.44–0.49; P < 0.001), those from Shikoku (OR, 0.69; 95% CI, 0.60–0.80; P < 0.001), those with chronic obstructive pulmonary disease (OR, 0.75; 95% CI, 0.68–0.84; P < 0.001), those with anemia (OR, 0.78; 95% CI, 0.62–0.98; P = 0.034), and those from Tohoku (OR, 0.83; 95% CI, 0.75–0.92; P < 0.001). CONCLUSIONS: Future efforts to rectify the regional variance in drug therapy conforming to the guidelines for the treatment of acute and chronic HF will help to extend the healthy lifespans of patients with HF. Further clarification is required to determine instances where triple therapy should be avoided based on patient factors, and appropriate countermeasures should be identified.
format Online
Article
Text
id pubmed-8078795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-80787952021-05-06 Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database Abe, Daisuke Inomata, Takayuki PLoS One Research Article BACKGROUND: This study aimed to collect data on “triple therapy” for heart failure (HF) with angiotensin-converting enzyme inhibitors (or receptor blockers), β-blockers, and mineralocorticoid receptor antagonists in all eight regions of Japan and clarify the reason for the selection of this therapeutic approach. METHODS AND RESULTS: We used data from April 2017 to March 2018 from the Medical Data Vision database (380 facilities) to analyze factors impacting triple therapy for HF. Among patients who were hospitalized for HF during the study period, 51,933 patients met the inclusion criteria and underwent further analyses. A reference value of 20.45% from Kanto was used to compare the eight Japanese regions. From the patient cohort, 10,006 (19.27%) patients receiving triple therapy were identified. The highest and lowest rates of triple therapy were in Chugoku (21.90%) and Shikoku (14.27%), respectively, suggesting regional differences in the use of triple therapy at discharge for patients with HF (P < 0.001). Regression analysis revealed a decrease in the administration of triple therapy for patients with chronic kidney disease (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.43–0.48]; P < 0.001), those aged 75 years and older (OR, 0.46, 95% CI: 0.44–0.49; P < 0.001), those from Shikoku (OR, 0.69; 95% CI, 0.60–0.80; P < 0.001), those with chronic obstructive pulmonary disease (OR, 0.75; 95% CI, 0.68–0.84; P < 0.001), those with anemia (OR, 0.78; 95% CI, 0.62–0.98; P = 0.034), and those from Tohoku (OR, 0.83; 95% CI, 0.75–0.92; P < 0.001). CONCLUSIONS: Future efforts to rectify the regional variance in drug therapy conforming to the guidelines for the treatment of acute and chronic HF will help to extend the healthy lifespans of patients with HF. Further clarification is required to determine instances where triple therapy should be avoided based on patient factors, and appropriate countermeasures should be identified. Public Library of Science 2021-04-27 /pmc/articles/PMC8078795/ /pubmed/33905452 http://dx.doi.org/10.1371/journal.pone.0249711 Text en © 2021 Abe, Inomata https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Abe, Daisuke
Inomata, Takayuki
Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database
title Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database
title_full Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database
title_fullStr Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database
title_full_unstemmed Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database
title_short Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database
title_sort actual state of “triple therapy” for heart failure patients in eight regions of japan: an analysis of a nationwide medical claims database
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078795/
https://www.ncbi.nlm.nih.gov/pubmed/33905452
http://dx.doi.org/10.1371/journal.pone.0249711
work_keys_str_mv AT abedaisuke actualstateoftripletherapyforheartfailurepatientsineightregionsofjapanananalysisofanationwidemedicalclaimsdatabase
AT inomatatakayuki actualstateoftripletherapyforheartfailurepatientsineightregionsofjapanananalysisofanationwidemedicalclaimsdatabase